TagCyx is a research based company based in Tokyo (Japan), founded in March 2007 as a spin out company of RIKEN. TagCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

Chief Executive Officer:

Chizuko Koseki, Ph.D

Board Members:

Akinori Mochizuki
Yoshiyuki Yamakawa
Junya Yamazaki
Takahiro Kono